How to buy Akorn stock

Akorn Inc is a drug manufacturers-specialty & generic business based in the US. Akorn shares (AKRX) are listed on the NASDAQ and all prices are listed in US Dollars. Akorn employs 2,227 staff and has a trailing 12-month revenue of around 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Akorn stock price (NASDAQ: AKRX)

Use our graph to track the performance of AKRX stocks over time.

Akorn shares at a glance

• Key figures

Information last updated 2020-10-22.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.04
200-day moving average more info button	$0.18
Wall St. target price	$2.00
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-3.82

Buy Akorn shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Akorn stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Akorn stock undervalued or overvalued?

Valuing Akorn stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akorn's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Akorn's EBITDA

Akorn's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $46.9 million.

The EBITDA is a measure of a Akorn's overall financial performance and is widely used to measure a its profitability.

Akorn financials

Revenue TTM	$721.3 million
Gross profit TTM	$252.7 million
Return on assets TTM	-0.94%
Return on equity TTM	-231.8%
Profit margin	-55.64%
Book value	$1.86
Market capitalisation more info button	$12 million

TTM: trailing 12 months

Akorn share dividends

We're not expecting Akorn to pay a dividend over the next 12 months.

Akorn share price volatility

Over the last 12 months, Akorn's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akorn's is 1.1428. This would suggest that Akorn's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Akorn overview

Akorn, Inc. , a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products.

Frequently asked questions

What percentage of Akorn is owned by insiders or institutions?
Currently 8.143% of Akorn shares are held by insiders and 75.927% by institutions. How many people work for Akorn?
Latest data suggests 2,227 work at Akorn. When does the fiscal year end for Akorn?
Akorn's fiscal year ends in December. Where is Akorn based?
Akorn's address is: 1925 West Field Court, Lake Forest, IL, United States, 60045 What is Akorn's ISIN number?
Akorn's international securities identification number is: US0097281069 What is Akorn's CUSIP number?
Akorn's Committee on Uniform Securities Identification Procedures number is: 009728106